Literature DB >> 29028660

Cumulative exposure of TDF is associated with kidney tubulopathy whether it is currently used or discontinued.

Takeshi Nishijima1, Yoshikazu Mutoh1, Yohei Kawasaki2, Kiyomi Tomonari1, Yoshimi Kikuchi1, Hiroyuki Gatanaga1, Shinichi Oka1.   

Abstract

OBJECTIVE: Tenofovir disoproxil fumarate (TDF) increases the risk of kidney tubular dysfunction (KTD). This study was conducted to elucidate whether KTD persists after discontinuation of TDF.
DESIGN: A prospective cross-sectional study which enrolled 941 HIV-1-infected patients.
METHODS: KTD was predefined as the presence of at least two abnormalities among the five tubular markers (fractional excretion of phosphate, fractional excretion of uric acid, β2 microglobulinuria, N-acetyl-β-D-glucosaminidase, nondiabetic glycosuria). Logistic regression model was used to examine the association between KTD and cumulative TDF use, as well as current status of TDF use.
RESULTS: In total, 94% of study patients were men (median age 45, estimated glomerular filtration rate 75 ml/min per 1.73 m, CD4 575 cells/μl. About 98% were on antiretroviral therapy. In total, 64% of the patients ever used TDF and 39% currently used TDF. Twenty-nine percent used TDF for more than 5 years. KTD was diagnosed in 116 (12%) patients. In multivariate model, more than 5 years of TDF exposure and current TDF use [odds ratio (OR) 4.2, 95% confidence interval (CI) 2.37-7.56], more than 5 years and past TDF use (OR 2.4, 95% CI 1.09-5.33), less than 5 years and current TDF (OR 2.4, 95% CI 1.24-4.85), and less than 5 years and past TDF (OR 2.4, 95% CI 1.22-4.64) were all significantly associated with KTD, with never TDF use as reference. The results were the same using 4 and 3 years of exposure as the cutoff. However, with 2 years exposure, both less than 2 years and current TDF (OR 2.3, 95% CI 0.84-6.20) and less than 2 years and past TDF (OR 1.9, 95% CI 0.73-4.93) were not associated with KTD, whereas both more than 2 years and current TDF and more than 2 years and past TDF were associated.
CONCLUSION: The association between cumulative TDF use and KTD was strong and robust. The results of the study suggested that TDF-related KTD might persist after discontinuation of TDF if patients used TDF for more than 2 years.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29028660     DOI: 10.1097/QAD.0000000000001667

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  5 in total

1.  CMCdG, a Novel Nucleoside Analog with Favorable Safety Features, Exerts Potent Activity against Wild-Type and Entecavir-Resistant Hepatitis B Virus.

Authors:  Nobuyo Higashi-Kuwata; Sanae Hayashi; Debananda Das; Satoru Kohgo; Shuko Murakami; Shin-Ichiro Hattori; Shuhei Imoto; David J Venzon; Kamalendra Singh; Stefan G Sarafianos; Yasuhito Tanaka; Hiroaki Mitsuya
Journal:  Antimicrob Agents Chemother       Date:  2019-03-27       Impact factor: 5.191

Review 2.  Tenofovir nephrotoxicity among Asians living with HIV: review of the literature.

Authors:  Takeshi Nishijima; Hiroyuki Gatanaga; Shinichi Oka
Journal:  Glob Health Med       Date:  2019-12-31

3.  Characteristics of 2-drug regimen users living with HIV-1 in a real-world setting: A large-scale medical claim database analysis in Japan.

Authors:  Daniel J Ruzicka; Mayuko Kamakura; Naho Kuroishi; Nobuyuki Oshima; Miyuki Yamatani; Jingbo Yi; Bruce Crawford; Kunihisa Tsukada; Shinichi Oka
Journal:  PLoS One       Date:  2022-06-14       Impact factor: 3.752

4.  Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity.

Authors:  Laura N Walti; Julia Steinrücken; Andri Rauch; Gilles Wandeler
Journal:  Open Forum Infect Dis       Date:  2018-10-24       Impact factor: 3.835

Review 5.  Osteoporosis and HIV Infection.

Authors:  Emmanuel Biver
Journal:  Calcif Tissue Int       Date:  2022-01-30       Impact factor: 4.000

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.